-
Antibody-Drug Conjugates Could Redefine Cancer Therapy
18 Sep 2025 05:20 GMT
… rituximab, and cetuximab. Over recent decades, these drugs have been … antibody-drug conjugates.
What Are Antibody-Drug Conjugates?
Antibody-drug conjugates … . For example, probody-drug conjugates may improve tumor … translated from El Medico Interactivo.
-
Alliance Webinar Showcases Cutting-Edge Advances in Cancer Treatment
16 Sep 2025 19:12 GMT
… combining avelumab with cetuximab versus avelumab … investigations that inform FDA approvals, clinical … thereby accelerating personalized medicine.
Collectively, the … Trials in OncologyASCO Annual Meeting 2025cancer treatment advancementsclinical trial …
-
Positive FDA Type B Meeting Enables Development of Oz-V for Oropharyngeal Cancer
10 Sep 2025 20:30 GMT
… the FDA regarding a trial evaluating the conditionally active biologic antibody drug … control arm will receive either cetuximab (Erbitux), docetaxel, or methotrexate … cancers, resistance mechanisms and treatment-related toxicities remain challenges.3 …
-
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
10 Sep 2025 12:00 GMT
… NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company … that may expand treatment sensitivity for resistant tumors … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
FDA Provides Guidance on Registrational Path for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma
09 Sep 2025 23:17 GMT
… biologic ROR2-targeted antibody-drug conjugate (ADC), ozuriftamab … of cetuximab (Erbitux), docetaxel, or methotrexate monotherapy.
The FDA’s … only 1 patient discontinued treatment due to a TRAE. … (oz-v) clinical trial data demonstrating compelling antitumor …
-
The Emerging Roles of Nano Drug Delivery Systems in Treatment of Osteoporosis-Current Knowledge, Challenges and Future Perspectives
09 Sep 2025 18:27 GMT
… Traditional Treatments and NDDSs
Traditional pharmacological treatments for … of drugs by specifically targeting active pharmaceutical ingredients … . Artif Cells Nanomed Biotechnol. 2018;46(sup3): … oral cavity cancer: cetuximab and cisplatin-conjugated gold …
-
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
08 Sep 2025 12:00 GMT
… a global clinical-stage biotechnology company focused on the … arm will receive either cetuximab, docetaxel, or methotrexate … FDA granted Fast Track Designation to Oz-V for the treatment … prospects, whether our clinical trials will support registration, …
-
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
05 Sep 2025 20:00 GMT
… GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company … 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
04 Sep 2025 13:15 GMT
… GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company … 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
04 Sep 2025 11:00 GMT
… unmet medical need,” said Gil Efron, CEO of Purple Biotech. … suppresses immune responses in treatment-resistant patients. Dr. … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
About
© 1995-2025